Ascendia

  MARKET NEWS

SciSparc Successfully Completed Production of its Proprietary Drug Candidate for its Upcoming Clinical Trial on Tourette Syndrome
NeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication & FDA Fast-Track Status
Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation
Anti-Properdin Antibody Demonstrates Efficacy in a Primate Model of Wet-AMD & Dry-AMD
Avenue Therapeutics Enters Transformational License Agreement With AnnJi Pharmaceutical 
EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion’s Patent Portfolio

  FEATURED EDITORIAL

  COMPANY PROFILE

Emergent CDMO is the contract development and manufacturing (CDMO) arm of Emergent (NYSE: EBS). Emergent CDMO has the scientific and regulatory compliance experience, end-to-end development and manufacturing expertise, and efficient technology transfer capabilities that can harness the urgency, acuity, and scalability required to bring life-saving, life-extending products to market. Even when the world changes around us and new challenges emerge, our mission stays the same — to improve and protect the health of billions of people around the globe by supporting innovative drug makers that make the seemingly impossible possible. We understand that which approach fits you best can be found where science and business strategy intersect, where dynamics like speed, cost, and regulatory approach are balanced in precise harmony. And as an integrated CDMO with the experience of an established biopharmaceutical company, Emergent stands ready to help reach your next clinical or commercial drug product milestone. Click here for more.

  EXCLUSIVE ONLINE CONTENT

TCR² Therapeutics & Adaptimmune Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

TCR² Therapeutics & Adaptimmune Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

TCR² Therapeutics Inc. and Adaptimmune Therapeutics recently announced entry into a definitive agreement under which Adaptimmune will combine with TCR² in an all-stock transaction to create a preeminent cell therapy company….

New Data Show CNM-Au8 Preserved ALS Patient Function & Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial

New Data Show CNM-Au8 Preserved ALS Patient Function & Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, recently announced new results showing preserved ALS….

Choosing the Best Drug Stability Solution for a Parental Product

Choosing the Best Drug Stability Solution for a Parental Product

The development of an injectable drug product always comes with the question of the best approach to retaining the product’s stability. We asked Dr. David Brett, Product and Service Manager at Vetter, what must be considered to deal with the….

Checkpoint Therapeutics Announces FDA Filing Acceptance of BLA for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics Announces FDA Filing Acceptance of BLA for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics, Inc. recently announced the US FDA has accepted for filing the Biologics License Application (BLA) for cosibelimab, Checkpoint’s investigational anti-PD-L1 antibody….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 15 – Polymerws & Biomaterials
March 22 – Excipients